<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325415</url>
  </required_header>
  <id_info>
    <org_study_id>D3820C00014</org_study_id>
    <nct_id>NCT01325415</nct_id>
  </id_info>
  <brief_title>A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects</brief_title>
  <official_title>A Single Center, Randomized, Double-blinded, Placebo-controlled, Open-label, Positive-controlled, Four-way Crossover Study to Assess the Effect of a Single Oral Dose NKTR-118 Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects on QTc interval in healthy males when
      administered a single dose of NKTR-118 compared with placebo and moxifloxacin. (QTc is a
      specific time interval that can be measured in a heart beat by taking Electrocardiogram
      (ECG))
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single Center, Randomized, Double-blinded, Placebo-controlled, Open-label,
      Positive-controlled, Four-way Crossover Study to Assess the Effect of a Single Oral Dose
      NKTR-118 Administration on QTc Interval Compared to Placebo, Using AVELOX (moxifloxacin) as a
      Positive Control, in Healthy Male Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of a single dose of NKTR-118 25 mg and 150 mg on the change in time-matched QTcF intervals compared with placebo</measure>
    <time_frame>30 days pre-dose through 4 treatment periods and follow up 71 days post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of a single dose of NKTR-118 25 mg and 150 mg on the change in time-matched QTcF intervals compared with placebo</measure>
    <time_frame>Follow up 71 days post dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of a single oral dose of moxifloxacin 400 mg on the changes in time-match QTcF intervals compared with placebo, which will be used as supporting data.</measure>
    <time_frame>30 days pre-dose through 4 treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collect adverse events to assess the safety after dosing of NKTR-118 25mg and 150 mg in healthy male subjects.</measure>
    <time_frame>30 days pre-dose through 4 treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of a single oral dose of moxifloxacin 400 mg on the changes in time-match QTcF intervals compared with placebo, which will be used as supporting data.</measure>
    <time_frame>Follow up 71 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collect adverse events to assess the safety after dosing of NKTR-118 25mg and 150mg in healthy male subjects.</measure>
    <time_frame>Follow up 71 days post dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Amount of NKTR-118 in Blood</condition>
  <condition>Variation in the Heart's Electrical Cycle</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NKTR-118 150 mg (6x25 mg tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NKTR-118 placebo (6x placebo tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin (1 x 400 mg tablet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-118</intervention_name>
    <description>25 mg tablet</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>400 mg tablet</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 18 to 50 years (inclusive) with suitable veins for
             cannulation or repeated venipuncture.

          -  Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and weight at least 50 kg
             but no more than 100 kg.

        Exclusion Criteria:

          -  Clinically significant medical history including severe allergies or a history of
             mental disorders or any cardiac history, history or presence of gastrointestinal,
             hepatic, or renal disease.

          -  Abnormal heart rhythm including any abnormal arrhythmias, marked sinus arrhythmias, or
             junctional rhythms.

          -  Known or suspected history of drug abuse, current smokers or those who have smoked
             and/or used nicotine products within 3 months prior to enrollment.

          -  Excessive intake of caffeine-containing products
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sostek, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Wilmington US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Matthews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Overland Park Kansas US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilie Ramos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca, Alderley Park, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1395&amp;filename=D3820C00014_Clinical_Study_Report_Synopsis.pdf</url>
    <description>D3820C00014 Clinical Study Report Synopsis</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy male volunteers</keyword>
  <keyword>cross-over study</keyword>
  <keyword>NKTR-118</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

